Stock AGRX AGILE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Agile Therapeutics, Inc.

Equities

AGRX

US00847L3087

Market Closed - OTC Markets
Other stock markets
 20:50:31 02/05/2024 BST 		5-day change 1st Jan Change
0.4048 USD -7.90% Intraday chart for Agile Therapeutics, Inc. +9.41% -79.24%
03-28 Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
03-28 Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Agile Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Top Premarket Gainers
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023
Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023
Agile Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023
Agile Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023
Agile Therapeutics, Inc. Announces Executive Changes
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
Agile Therapeutics, Inc. Announces New Agreement with vitaCare Prescription Services to Improve Access to Twirla
Agile Therapeutics Closes $7.5 Million Public Offering
Agile Therapeutics Prices $7.5 Million Public Offering of Common Stock, Warrants
Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Agile Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2023
Agile Therapeutics, Inc. Provides Revenue Guidance for the First Quarter 2023
Agile Therapeutics Gets Board Approval for 1-For-50 Reverse Stock Split
MÄRKTE USA/Wall Street erholt sich von Fed-Dämpfer leicht
MÄRKTE USA/Wall Street vor leichter Erholung nach Fed
Agile Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGRX Stock
  4. News Agile Therapeutics, Inc.
  5. Other languages